Condition: Relapsed/Refractory Large B-cell Lymphoma · Sponsor: Peter MacCallum Cancer Centre, Australia
This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Royal Prince Alfred Hospital | Camperdown, New South Wales, Australia | Not Yet Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| Royal Brisbane and Women's Hospital | Herston, Queensland, Australia | Not Yet Recruiting |
| Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| Fiona Stanley Hospital | Murdoch, Western Australia, Australia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06414148